The RCT for aflibercept in BRVO is not yet published (“Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEATM in Patients With Branch Retinal Vein Occlusion (BRVO)”, NCT01521559, Regeneron Pharmaceuticals, source: clinicaltrials.gov). This evidence concerns the gene VEGFA and retinal vein occlusion.